EA202092861A1 - Специфичные в отношении злокачественной опухоли t-клеточные рецепторы - Google Patents

Специфичные в отношении злокачественной опухоли t-клеточные рецепторы

Info

Publication number
EA202092861A1
EA202092861A1 EA202092861A EA202092861A EA202092861A1 EA 202092861 A1 EA202092861 A1 EA 202092861A1 EA 202092861 A EA202092861 A EA 202092861A EA 202092861 A EA202092861 A EA 202092861A EA 202092861 A1 EA202092861 A1 EA 202092861A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
agent
vector
vaccine
pharmaceutical composition
Prior art date
Application number
EA202092861A
Other languages
English (en)
Inventor
Эндрю Сьюэлл
Гарри Долтон
Original Assignee
Юниверсити Коллидж Кардифф Консалтентс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Коллидж Кардифф Консалтентс Лимитед filed Critical Юниверсити Коллидж Кардифф Консалтентс Лимитед
Publication of EA202092861A1 publication Critical patent/EA202092861A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к новому пептиду против злокачественной опухоли; вектору, кодирующему его; фармацевтической композиции или иммуногенному агенту, или биспецифическому агенту, или вакцине, содержащим указанный пептид против злокачественной опухоли; к применению указанного пептида против злокачественной опухоли, вектора, фармацевтической композиции, иммуногенного агента, биспецифического агента или вакцины для лечения злокачественной опухоли; к способу лечения злокачественной опухоли с использованием указанного пептида против злокачественной опухоли, вектора, фармацевтической композиции, иммуногенного агента, биспецифического агента или вакцины; и к комбинированному терапевтическому средству для лечения злокачественной опухоли, содержащему указанный пептид против злокачественной опухоли, вектор, фармацевтическую композицию, иммуногенный агент, биспецифический агент или вакцину.
EA202092861A 2018-06-25 2019-06-25 Специфичные в отношении злокачественной опухоли t-клеточные рецепторы EA202092861A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810358.0A GB201810358D0 (en) 2018-06-25 2018-06-25 Cancer-specific t-cell receptors
PCT/GB2019/051785 WO2020002899A1 (en) 2018-06-25 2019-06-25 Cancer-specific t-cell receptors

Publications (1)

Publication Number Publication Date
EA202092861A1 true EA202092861A1 (ru) 2021-04-19

Family

ID=63042790

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092861A EA202092861A1 (ru) 2018-06-25 2019-06-25 Специфичные в отношении злокачественной опухоли t-клеточные рецепторы

Country Status (15)

Country Link
US (1) US20210196807A1 (ru)
EP (1) EP3810175A1 (ru)
JP (1) JP2021529181A (ru)
KR (1) KR20210023822A (ru)
CN (1) CN112292392A (ru)
AU (1) AU2019295371A1 (ru)
BR (1) BR112020023182A2 (ru)
CA (1) CA3099677A1 (ru)
EA (1) EA202092861A1 (ru)
GB (1) GB201810358D0 (ru)
IL (1) IL279621A (ru)
MX (1) MX2020013601A (ru)
SG (1) SG11202010976PA (ru)
WO (1) WO2020002899A1 (ru)
ZA (1) ZA202006675B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220233662A1 (en) * 2020-12-30 2022-07-28 University College Cardiff Consultants Ltd. Novel peptide
WO2023118820A1 (en) * 2021-12-21 2023-06-29 Continuum Life Sciences Limited Cancer specific t-cell receptors
GB202211194D0 (en) 2022-08-01 2022-09-14 Univ College Cardiff Consultants Ltd Novel TCRs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038002A1 (en) * 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
US10835585B2 (en) * 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens

Also Published As

Publication number Publication date
CN112292392A (zh) 2021-01-29
AU2019295371A1 (en) 2020-12-17
SG11202010976PA (en) 2021-01-28
IL279621A (en) 2021-03-01
BR112020023182A2 (pt) 2021-02-09
CA3099677A1 (en) 2020-01-02
US20210196807A1 (en) 2021-07-01
MX2020013601A (es) 2021-03-09
KR20210023822A (ko) 2021-03-04
EP3810175A1 (en) 2021-04-28
WO2020002899A1 (en) 2020-01-02
GB201810358D0 (en) 2018-08-08
ZA202006675B (en) 2022-09-28
JP2021529181A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2023014093A (es) Compuestos que interactuan con glicano y metodos de uso.
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CL2019002533A1 (es) Vacuna.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA202092861A1 (ru) Специфичные в отношении злокачественной опухоли t-клеточные рецепторы
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
EA201791736A1 (ru) Комбинированная терапия для лечения рака
CR20220207A (es) Compuestos terapéuticos y métodos de uso
EA202091015A1 (ru) Новый т-клеточный рецептор
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2019013071A (es) Metodo de tratamiento inmunoterapeutico de un tumor.
NZ762312A (en) Anti-pacap antibody
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
MX2023008375A (es) Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202192757A1 (ru) Способ лечения опухолей
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба